Ki-67、C-erb-B2及nm23在前列腺癌中的表达及意义  

Expressions of Ki-67、C-erb-B2 and nm23 in prostate cancer

作　　者：毕丽荣[1] 杨华[1] 刘仲祥[1] 王连有[1] 

机构地区：[1]吉林大学中日联谊医院病理科,吉林长春130033

出　　处：《中国实验诊断学》2010年第1期90-92,共3页Chinese Journal of Laboratory Diagnosis

摘　　要：目的探讨相关癌基因等在前列腺癌中表达的意义,从病理学角度了解前列腺癌的生物学特性。方法根据最新WHO分类标准(2002)及Gleason分级法进行组织学分级和对比性分析;应用免疫组织化学技术,观察增殖细胞核抗原Ki-67、原癌基因c-erbB-2、抑癌基因nm23在前列腺癌中的表达情况。结果近81.69%的患者在Gleason分级8分以上;Ki-67与组织学分级之间有显著性差异,(P<0.05);肿瘤的恶性程度越高,肿瘤细胞的Ki-67表达越强;c-erbB-2随着肿瘤恶性程度增高,其阳性表达率也在上升(P<0.05),且c-erbB-2的阳性表达率与Gleason分级之间有显著性差异;nm23的阳性表达率与Gleason分级之间存在显著的差异性(P<0.05),Gleason分值越高,nm23阳性表达率也在增加。结论Ki-67、c-erbB-2、nm23可作为判断前列腺癌生物学行为即肿瘤预后的可靠指标。Objective Purpose To explore the expression of Ki-67, c-erbB-2 and nm23 in prostate cancer and its significance respectively. Methods Immunohistochemical staining method was used to detect the expression of Ki-67, c-erbB-2 and nm23 in 113 prostate cancer cases. Results According to ~$ classification of WHO and Gleason grade, there were 81.69% cases G 〉 8. There were10.35% ,22.72% ,58.33% cases （G 〈 7,G = 7, G 〉 7） positive respectively for Ki-67 and 10.53%, 18.18% ,48.33% cases （G 〈 7,G= 7,G〉 7） positive for C-erbB-2. For nm23 expression was 36.84% ,45.45% ,73.33% cases （G〈 7,G = 7,G 〉 7） .And significant different was determined between three parameters and Gleanson grade respectively. Conclusion ＇ There were obvious rela- tionships among the expression of Ki-67, c-erbB-2, nm23 and Gleason grade. All P 〈 0.05, Ki-67, e-erbB=2, nm23 axe reliable pa- rameters for prognosis prostate cancer.

关 键 词：前列腺癌 病理诊断 免疫组化 预后 

分 类 号：R737.25[医药卫生—肿瘤]